Radiation dose to rectum in high-dose-rate brachytherapy with a single implant and two fractions for prostate cancer, and its prediction by prostate volume
详细信息 查看全文
- 作者：Noritaka Shimizu ; Yasutaka Noda ; Morio Sato…
- 关键词：High ; dose ; rate brachytherapy ; Rectal bleeding ; Prostate cancer ; Radiation toxicity ; Prostate volume ; Rectal dose–volume parameters
- 刊名：Radiological Physics and Technology
- 出版年：2015
- 出版时间：January 2015
- 年：2015
- 卷：8
- 期：1
- 页码：18-25
- 全文大小：387 KB
- 参考文献：1. Stromberg J, Martinez A, Gonzalez J, Edmundson G, Ohanian N, Vicini F, Hollander J, Gustafson G, Spencer W, Yan D, Brabbins D. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 1995;33:161-1. CrossRef
2. Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, Spencer W, Stromberg J, Huang R, Vinci F. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:316-7. CrossRef
3. Demanes JD, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, Gustafson G. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81:1286-2. CrossRef
4. Rogers CL, Alder CS, Rogers LR, Hopkins SA, Platt ML, Childs LC, Crouch RH, Hansen RS, Hayes JK. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol. 2012;187:109-6. CrossRef
5. Morton G, Loblaw A, Cheung P, Szumacher E, Chahal M, Danjoux C, Chung HT, Deabreu A, Mamedov A, Zhang L, Viqneault E, Springer C. Is single fraction 15?Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol. 2011;100:463-. CrossRef
6. Yoshioka Y, Nose T, Yoshida K, Inoue T, Yamazaki H, Tanaka E, Shiomi H, Imai A, Nakamura S, Shimamoto S, Inoue T. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 2000;48:675-1. CrossRef
7. Hiratsuka J, Jo Y, Yoshida K, Nagase N, Fujisawa M, Imajo Y. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:684-0. CrossRef
8. Akimoto T, Katoh H, Kitamoto Y, Tamaki T, Harada K, Shirai K, Nakano T. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys. 2006;65:364-0. CrossRef
9. Sato M, Mori T, Shirai S, Kishi K, Inagaki T, Hara I. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:1002-. CrossRef
10. Prada JP, Mendez L, Fernandez J, González H, Jiménez I, Arrojo E. Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer. Radiat Oncol. 2012;7:31. CrossRef
11. Morton CG, Loblaw AD, Chung H, Tsang G, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Batchelar D, Danjoux C, Szumacher E. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;80:1299-05. CrossRef
12. Wattson AD, Chen MH, Moul WJ, Moran BJ, Dosoretz DE, Robertson CN, Polascik TJ, Braccioforte MN, Salenius SA, D’Amico AV. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. Int J Radiat Oncol Biol Phys. 2012;82:e773-.
文摘
We aimed to clarify the differences between the estimated rectal dose (ERD) and the first measured dose (FMD) and second measured dose (SMD) to the rectum during high-dose-rate (HDR) brachytherapy, and to predict FMD from the prostate volume (PV) or the rectal dose–volume parameters (RDVPs). ERD, FMD, and SMD were assessed with a rectal dosimeter during HDR brachytherapy of 18?Gy given in two fractions to 110 patients (48 hormone recipients, 62 hormone-na?ve patients) with prostate cancer. The correlations between FMD and PV, and between FMD and RDVP (D 2ml-em class="a-plus-plus">D 5ml) were investigated. ERD (mean?±?SD) was 219?±?44?cGy, FMD was 255?±?52?cGy, and SMD was 298?±?63?cGy, which differed significantly (p?p?